Every S-1 that United Compute Inc (SHPH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow SHPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SHPH filings page.
Shuttle Pharmaceuticals Holdings, Inc. is registering up to 2,229,300 shares of common stock and pre-funded warrants to purchase up to 2,229,300 shares in a best efforts public offering. The assumed public offering price is $1.57 per share or pre-funded warrant, implying up to $3.5 million in gross proceeds and estimated net proceeds of about $3.03 million if fully sold.
The company plans to use up to $1.5 million for future marketing, including a new agreement with IR Agency LLC, and the balance for working capital and general corporate purposes. Shuttle recently acquired the AI-driven Molecule.ai platform and discontinued clinical trials of its lead drug candidate, and it preliminarily estimates a 2025 net loss between $10.9 million and $12.1 million with no revenue.
Shuttle Pharmaceuticals Holdings, Inc. has filed an S-1 to offer up to 2,229,300 shares of common stock, or pre-funded warrants in lieu of shares, plus the common shares underlying those pre-funded warrants. The assumed price is $1.57 per share, matching the February 5, 2026 Nasdaq close.
The company recently acquired the Molecule.ai AI drug-discovery platform and has discontinued clinical trials of its lead drug candidate, Ropidoxuridine, signaling a shift toward AI-driven discovery. Preliminary 2025 results show no revenue and a higher net loss of $10.9–$12.1 million versus $9.1 million in 2024, driven largely by a jump in general and administrative expenses tied to $3.6 million of investor-relations advertising.
As of December 31, 2025, Shuttle expects a working capital deficit of $0.7–$0.8 million and $9.8 million of intangible assets from the Molecule.ai acquisition, with $6.4 million of contingent and payable consideration remaining. Net proceeds from this offering are estimated at about $3.03 million, with $1.5 million earmarked for marketing and the balance for working capital and general corporate purposes.
Shuttle Pharmaceuticals Holdings, Inc. is registering the resale of 625,156 shares of common stock issuable upon exercise of a pre-funded warrant held by a single investor. The company will not receive proceeds from these resale transactions; the warrant was sold in a November 2025 private placement for aggregate gross proceeds of approximately $2.5 million and carries a nominal exercise price of $0.001 per share.
The warrant is immediately exercisable but capped so the holder cannot own more than 4.99% of outstanding common stock at any time. Shares outstanding were 1,603,285 as of December 10, 2025, when the Nasdaq last reported a common stock price of $1.85 per share. The company also reports acquiring the Molecule.ai AI-driven drug discovery platform and discontinuing clinical trials of lead candidate Ropidoxuridine, a strategic shift that management notes could materially affect future plans and financial position. Prior audited financial statements include an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern.
Shuttle Pharmaceuticals Holdings, Inc. is registering 625,156 shares of common stock for resale by a single selling stockholder. These shares are issuable upon exercise of a pre-funded warrant that was sold in a November 2025 private placement for approximately $2.5 million of gross proceeds already received by the company, so Shuttle will not receive any cash from the resale of these shares.
Shuttle Pharma is a development-stage oncology company focused on radiation-enhancing therapies, led by its Ropidoxuridine program, which has advanced into a Phase II clinical trial in brain cancer patients undergoing radiation therapy after a completed Phase I study. The company highlights substantial risks, including the potential pressure on its share price from resale of these registered shares and other issuances, as well as a going concern uncertainty noted by its independent auditor. Shuttle is also pursuing a contemplated asset acquisition from Molecule, which it cautions may carry integration and execution risks.